Trump Executive Order Boosts Psychedelic Research, Yet Racial Disparities Loom

Trump Signs Executive Order to Accelerate Psychedelic Access

President Donald Trump signed an executive order Wednesday aimed at speeding up the use of psychedelics in clinical research and treatment. He was flanked by podcaster Joe Rogan and members of the Make America Healthy Again (MAHA) movement, signaling a new political alliance around the controversial substances.

The order directs federal agencies to reduce regulatory barriers for studies involving drugs like psilocybin, MDMA, and LSD. Supporters argue that decades of stigma have blocked potentially breakthrough therapies for PTSD, depression, and addiction.

Experts Warn of Growing Equity Gap

However, health equity researchers caution that the psychedelic renaissance may bypass communities of color. The current boom is largely white and affluent, said Dr. Maya Rivera, a public health professor at Columbia University. Without deliberate policy, we risk recreating the same disparities seen in other mental health treatments.

Studies show that Black and Hispanic patients are significantly less likely to be referred to psychedelic trials. Cost and cultural stigma also pose barriers, even as legal access expands.

Read more: Background on psychedelic history | What this means for equity

Background: From Ancient Rituals to Club Drug Stigma

Use of naturally occurring and synthetic hallucinogens traces back to the Neanderthals. These substances have been central to spiritual and healing practices for millennia across cultures.

Yet in modern medicine, psychedelics were long written off as club drugs with little clinical value. The DEA classified them as Schedule I substances in the 1970s, halting most research until recent years.

The MAHA-Rogan-Trump Connection

Trump’s order comes after growing advocacy from figures like Joe Rogan, who has hosted psychedelic researchers on his podcast. The MAHA movement, a coalition of alternative health proponents, has also pushed for deregulation.

Critics worry that this alliance privileges certain voices while ignoring the historical and cultural use of psychedelics in Indigenous and minority communities.

What This Means: A Two-Speed Revolution

If equity is not prioritized, the revolution could deepen existing health care divides. White patients may gain access to cutting-edge therapies, while people of color remain locked out due to cost, lack of diverse trial participants, and lingering legal risks.

Advocates urge the administration to include community-based clinics and sliding-scale pricing in future rules. We need a psychedelic policy that heals, not divides, said Dr. Rivera.

Urgent Next Steps

• Funding for diversity in clinical trials
• Insurance coverage for psychedelic therapies
• Cultural competency training for providers

The executive order is a first step. Without these measures, the psychedelic revolution may leave behind the very communities that have used these substances for centuries.